- $1.52bn
- $1.20bn
- $411.33m
Brief: Armata Pharmaceuticals Announces New Financing And Leadership Transition
Brief: Innoviva Specialty Therapeutics Announces FDA Approval For Xacduro
Brief: Innoviva Reports First Quarter 2023 Financial Results And Highlights Recent Company Progress
Brief: Innoviva posts Q1 EPS USD 0.42
Brief: Innoviva Announces Retirement Of Board Chairman
Innoviva Inc expected to post earnings of 23 cents a share - Earnings Preview
Innoviva jumps as FDA panel backs multidrug-resistant bacterial infections drug
US FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections (updated)
Brief: Sulbactam-Durlobactam Unanimously Recommended For Approval By FDA Advisory Committee
US FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections
Innoviva rises as FDA staff says no new concerns for antibiotic
Brief: Innoviva Announces FDA Advisory Committee Meeting To Review Sulbactam-Durlobactam (Sul-Dur), An Investigational Targeted Antibiotic
Innoviva Inc reports results for the quarter ended in December - Earnings Summary
Brief: Innoviva Reports Q4 2022 Financial Results And Highlights Recent Company Progress
Brief: Innoviva Posts Q4 royalty revenue USD 51.216 million
Irenic Capital urges Theravance to conduct review, add shareholder to board
Innoviva Inc expected to post earnings of 23cents a share - Earnings Preview
Brief: Innoviva Announces FDA Acceptance And Priority Review Of New Drug Application For Sulbactam-Durlobactam
Brief: Innoviva Reports Third Quarter 2022 Financial Results